Inactive Instrument

ImmunoPrecise Antibodies Ltd. Stock price Toronto S.E.

Equities

IPA

CA45257F2008

Pharmaceuticals

Sales 2024 * 24.59M 18.15M Sales 2025 * 29.82M 22.01M Capitalization 54.13M 39.95M
Net income 2024 * -12M -8.86M Net income 2025 * -9M -6.64M EV / Sales 2024 * 2.2 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.82 x
P/E ratio 2024 *
-4.33 x
P/E ratio 2025 *
-5.87 x
Employees 102
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.44%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 18-02-20
Director of Finance/CFO - 23-09-28
Chief Tech/Sci/R&D Officer - 21-06-30
Members of the board TitleAgeSince
Chairman - -
Director/Board Member 59 23-09-04
Chief Executive Officer - 18-02-20
More insiders
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
More about the company
  1. Stock
  2. Equities
  3. Stock ImmunoPrecise Antibodies Ltd.
  4. Stock ImmunoPrecise Antibodies Ltd. - Toronto S.E.